Neurogastrx believes its drug could treat one of the most troublesome side effects of one of the industry's biggest blockbusters. On Wednesday, the Boston-area biotech said that its experimental drug ...

U.S. pharmaceutical giant Eli Lilly is exploring whether obesity drugs could be used to curb joblessness after signing a ...

A global survey of breast cancer patients reveals a gap in support services for managing the mental and physical side effects experienced by those undergoing treatment.

A review of the medical records of thousands of adolescents treated for obesity found that kids who received the GLP-1 ...

Tirzepatide, a cutting-edge medication initially approved for the treatment of type 2 diabetes, has shown remarkable potential in facilitating significant weight loss. This dual GIP and GLP-1 receptor ...

Providing coverage for weight-loss drugs such as Wegovy and Ozempic is forcing employers to make some critical decisions.

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...

Chinese insulin maker Gan & Lee Pharmaceuticals is wading into the obesity world with an injectable GLP-1 agonist that beat Novo Nordisk's Ozempic (semaglutide) at lowering glycated hemoglobin (HbA1c) ...

Hoping your company will begin paying for anti-obesity medications like Wegovy? You may be in luck. A growing number of ...

GLP-1 agonists work by triggering the pancreas to produce more insulin, which reduces blood sugar levels in those with type 2 ...

Half of people who develop blood poisoning, otherwise known as sepsis, are dead within a couple of years, a new study finds.

India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...